The differentially expressed GPR65 [47], DPP4 [48], and CXCR6 [23, 24] are involved in the anti-cancer efficacy of PD-1 blockade by affecting the recruitment of tumor-associated macrophages or CD8 + T cells. This evidence concerns the gene PDCD1 and neoplasm.